Skip to main content
. Author manuscript; available in PMC: 2015 Apr 8.
Published in final edited form as: Am J Ophthalmol. 2014 Aug 1;158(5):1071–1078. doi: 10.1016/j.ajo.2014.07.036

Figure 3.

Figure 3

Graph showing omega-3 supplementation and systemic vascular endothelial growth factor (VEGF) A concentrations in wet age-related macular degeneration and control patients. Plasma VEGF levels demonstrating no significant difference between group 4 (control; n = 8) and group 1 (anti-VEGF plus omega-3; n = 9; P = .7361), group 2 (anti-VEGF alone; n=6; P=.6194), and group 3 (treatment naïve, starting on anti-VEGF; n = 7; P = .9474, t test).